Please provide your email address to receive an email when new articles are posted on . A subcutaneous injection of leuprolide acetate every 6 months was effective and well tolerated in treating ...

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.

MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...

The Food and Drug Administration has cleared Amneal’s leuprolide acetate for injection, which is indicated in the palliative treatment of advanced prostatic cancer. “We are making tremendous progress ...

– CAMCEVI™ is the first ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required – Eligible patients prescribed ...

DURHAM, N.C., April 4, 2022 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology ...

Credit: Getty Images. Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist. Camcevi ® (leuprolide mesylate) 42mg injection ...